Seroba Kernel
Press Archives
2009 Press Releases
2008 Press Releases
2007 Press Releases
2006 Press Releases
2005 Press Releases
2004 Press Releases
2002 Press Releases

2005 Press
12th December
Alimentary Health Ltd. announces Gastrointestinal Licensing Agreement with Procter & Gamble
29th November
Deerac Fluidics Incorporates Sales and Service Subsidiary in the US
27th September
AGI Therapeutics Completes Enrolment of its Phase II Clinical Trial for AGI-001 in Functional Dyspepsia
12th September
Deerac Fluidics Appoints Zinsser Analytic to Distribute HTS and Genomics Liquid Handling Systems in Germany, Switzerland and Austria
29th August
Deerac Fluidics Awarded European Commission Contract for Low Volume Measurement Device
20th June
TriMed Research, Inc. Secures €5 Million in Series A Funding
15th June
Funding Advances Fight Against Type 2 Diabetes & Obesity
28th April
Alimentary Health Announces Agreement with Mead Johnson Nutritionals
24th February
Opsona Therapeutics Announces A-Round Financing
13th January
Broad Institute to implement low-volume DNA sequencing process using Deerac’s Equator™ products
Alimentary Health Ltd. announces Gastrointestinal Licensing Agreement with Procter & Gamble


Cork, Ireland, December 12, 2005: Alimentary Health Ltd (AH), a biotechnology company based in Cork, Ireland today announced that it has signed a worldwide licensing agreement with The Procter & Gamble Company (NYSE:PG) for Gastrointestinal (GI) indications.

AH was established in 1999 and is a leader in pioneering the development of safe and effective therapeutics for GI and other indications. "This deal is the culmination of a close working partnership with P&G over a number of years and will transition us into a revenue generating company" says Barry Kiely, CEO of AH. "We are proud to be associated with such a leading multi-national company".

"P&G is excited about the opportunity to formalise our work with Alimentary Health and continue our collaboration with such a leading edge company," said Rowena Pullan, Director, Global Personal Health Care Research and Development.

GI disorders are common and the treatment of GI diseases constitutes one of the largest pharmaceutical markets in the world with an annual market in excess of $20 billion.

About Alimentary Health

Alimentary Health is a development stage specialty biotechnology company linked to the Alimentary Pharmabiotic Centre (APC) based at University College Cork, Cork, Ireland. Alimentary Health is focused on the discovery, development and commercialization of proprietary treatments for gastrointestinal disorders and other inflammatory conditions.

About P&G (NYSE:PG)

Three billion times a day, P&G brands touch the lives of people around the world. The company has one of the strongest portfolios of trusted, quality, leadership brands, including Pampers®, Tide®, Ariel®, Always®, Whisper®, Pantene®, Mach3®. Bounty®, Dawn®, Pringles®, Folgers®, Charmin®, Downy®, Lenor®, Iams®, Crest®, Oral-B®, Actonel®, Duracell®, Olay®, Head & Shoulders®, Wella, Gillette®, and Braun. The P&G community consists of almost 140,000 employees working in over 80 countries worldwide. Please visit www.pg.com for the latest news and in-depth information about P&G and its brands.

About APC

The Alimentary Pharmabiotic Centre (APC) is a Science Foundation Ireland (SFI) funded research centre headquartered in University College Cork (UCC), with scientists and clinicians also based in Teagasc Moorepark, Cork University Hospital and Alimentary Health Ltd. The APC is investigating mechanisms by which intestinal bacteria influence health and disease and is developing new therapies for lifelong debilitating gastrointestinal diseases such as gastroenteritis, ulcerative colitis and Crohn’s disease. For information please visit http://apc.ucc.ie

Contact Information

Dr Barry Kiely, CEO
Alimentary Heath
Tel: + 353 (0)21 4774715
Email: bkiely@alimentaryhealth.ie
Dr. Crystal W. Harrell
P&G Health Sciences Institute
Tel: 513-622-2880
Email: Harrell.cw@pg.com